The new contractual arrangements will come into force from 1 October 2019 and will help to deliver the ambitions set out in the NHS Long Term Plan. It presents a 5-year deal setting out how community pharmacy will support delivery of
The document is a summary of changes to the community pharmacy contractual framework for 2019/20 to 2023/24, which was published jointly by the Department of Health and Social Care, the Pharmaceutical Services Negotiating Committee (PSNC).
Letter from from Ed Waller to the Directors of Commissioning, Regional Heads of Primary Care, Heads of Primary Care, CCG Clinical Leads and Accountable Officers about the community pharmacy contractual framework.
This briefing summarises the elements of the NHS long term plan implementation framework that are of most relevance to community pharmacy contractors and local pharmaceutical committees.
Report from the House of Commons Health and Social Care Committee that finds despite the rescheduling of medicinal cannabis, very few prescriptions have been issued. One of the many reasons for this is because of the gaps in the evidence
This is the equality impact assessment for the consultation ‘Items which should not routinely be prescribed in primary care – a consultation on guidance for CCGs’ which ran between 21 July and 21 October 2017.
‘Items which should not routinely be prescribed in primary care – a consultation on guidance for CCGs’ ran between 21 July and 21 October 2017 – these are the results to this consultation.
A letter to suppliers giving an update on ensuring a continued supply of medicines and medical products if the UK leaves the EU with no deal. The letter sets out: how the government plans to ensure a continued supply of
The NHS must be an active participant with industry in delivering the shared objective of outstanding patient outcomes. In part that is because it is a monopoly purchaser but also because the NHS should be where innovative products are developed
These Regulations (which come into force immediately before exit day) are made to correct drafting defects and omissions in the Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775) and the Medical Devices (Amendment etc.) (EU Exit) Regulations 2019
The national dose banding tables are to be used by hospital trust pharmacy teams to ensure a standard approach to dose banding of chemotherapy across all hospital trusts.
Date of report: 11 March 2019 Ref: 2019-0086 Deceased name: Terence Bradfield Coroners name: Deborah Archer Coroners Area: Plymouth Torbay and South Devon Category: Hospital Death (Clinical Procedures and medical management) related deaths This report is being sent to: University
This briefing document provides information on supporting primary care network for pharmacy teams.
This is a letter from Matthew Swindells and provides information on the nationally set reference price for adalimumab.
This briefing is intended to enable Local Pharmaceutical Committees (LPCs) to help contractors to get involved with Primary Care Networks.
A suite of policy booklets to guide NHS commissioning / contracting teams in commissioning high quality community pharmaceutical services.
The NHS estimates that it lost around £212 million in 2017-18 from people incorrectly claiming exemption from prescription and dental charges. However rules around entitlement are overly complicated leading to genuine mistakes and confusion for many people. in response NHSBSA
Interim NHS People Plan, developed collaboratively with national leaders and partners, sets a vision for how people working in the NHS will be supported to deliver care and identifies the actions we will take to help them. It finds NHS
This document provides an update for key clinical and non-clinical stakeholders about the role of biosimilar medicines in the NHS in England and to support the safe, effective and consistent use of all biological medicines, including biosimilar medicines, to the
Patients Association report that finds patients with common conditions such as rheumatoid arthritis, psoriasis and ulcerative colitis are being switched to new medicines without receiving the support they need to understand any changes, or to monitor and manage side effects